Price Alert: Shares of Oyster Point Pharma (OYST) Trade 12.06% Higher at Midday June 23

Equities Staff  |

Oyster Point Pharma Inc (NASDAQ: OYST) has gained $0.45 (12.06%) and is currently sitting at $4.18, as of 12:05:38 est on June 23.

40,382 shares have been traded today.

The Company fell 10.55% over the last 5 days and shares lost 3.62% over the last 30 days.

Oyster Point Pharma is set to release earnings on 2022-08-04.

For technical charts, analysis, and more on Oyster Point Pharma visit the company profile.

About Oyster Point Pharma Inc

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma's lead product candidate, OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit.

To get more information on Oyster Point Pharma Inc and to follow the company's latest updates, you can visit the company's profile page here: Oyster Point Pharma Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content